CT
CERE

Cambridge Trust’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Cambridge Trust’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-250
Closed -$10.6K – 726
2023
Q4 		$10.6K Buy
+250
New +$7.18K ﹤0.01% 566

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Cambridge Trust's CERE Position: Q1 2024 in Review

Cambridge Trust sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 250 shares — an estimated $10.6K sold.

Cambridge Trust first reported a position in CERE in Q4 2023 and held it in 1 quarter. The position peaked at $10.6K in Q4 2023. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

  • Cambridge Trust reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Cambridge Trust sold 250 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $10.6K.
  • Cambridge Trust first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Cambridge Trust's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $10.6K in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.